CLINICAL_TRIALS
trial_result
· 2017-05-25
Clinical Trial Update: DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma [Phase 2]
Summary
Phase 2 trial DN24-02 as adjuvant therapy for high-risk HER2-positive urothelial carcinoma was terminated; results were posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dendreon | Conditions: Urothelial Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2017-05-25